PL2404922T3 - Związki chinoksalinowe - Google Patents

Związki chinoksalinowe

Info

Publication number
PL2404922T3
PL2404922T3 PL10748823T PL10748823T PL2404922T3 PL 2404922 T3 PL2404922 T3 PL 2404922T3 PL 10748823 T PL10748823 T PL 10748823T PL 10748823 T PL10748823 T PL 10748823T PL 2404922 T3 PL2404922 T3 PL 2404922T3
Authority
PL
Poland
Prior art keywords
quinoxaline compounds
quinoxaline
compounds
Prior art date
Application number
PL10748823T
Other languages
English (en)
Inventor
Hiroyuki Kaizawa
Mari Sugita
Hidenori Azami
Ryushi Seo
Takaho Nomura
Satoshi Yamamoto
Hirofumi Yamamoto
Kazuyuki Tsuchiya
Hideki Kubota
Kazunori Kamijo
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL2404922T3 publication Critical patent/PL2404922T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL10748823T 2009-03-05 2010-03-04 Związki chinoksalinowe PL2404922T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009052577 2009-03-05

Publications (1)

Publication Number Publication Date
PL2404922T3 true PL2404922T3 (pl) 2017-03-31

Family

ID=42709784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10748823T PL2404922T3 (pl) 2009-03-05 2010-03-04 Związki chinoksalinowe

Country Status (16)

Country Link
US (2) US8357688B2 (pl)
EP (1) EP2404922B1 (pl)
JP (1) JP5609861B2 (pl)
KR (1) KR20110132559A (pl)
CN (1) CN102341399A (pl)
AU (1) AU2010219598A1 (pl)
BR (1) BRPI1009287A2 (pl)
CA (1) CA2754457A1 (pl)
ES (1) ES2612954T3 (pl)
IL (1) IL214918A0 (pl)
MX (1) MX2011009314A (pl)
PL (1) PL2404922T3 (pl)
PT (1) PT2404922T (pl)
RU (1) RU2011140333A (pl)
TW (1) TW201043632A (pl)
WO (1) WO2010101230A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009314A (es) * 2009-03-05 2011-10-11 Astellas Pharma Inc Compuesto de quinoxalina.
AU2010289397B2 (en) 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
KR20130097178A (ko) * 2010-09-07 2013-09-02 아스텔라스세이야쿠 가부시키가이샤 퀴녹살린 화합물
KR101567610B1 (ko) 2010-11-04 2015-11-09 주식회사 엘지화학 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자
WO2012119046A2 (en) * 2011-03-02 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
JO3116B1 (ar) * 2011-10-07 2017-09-20 Eisai R&D Man Co Ltd مشتق بيرازولوكينولين كمثبطات ل pde9
EP2828267B1 (en) 2012-03-23 2019-10-30 Memorial Sloan-Kettering Cancer Center TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
JP6244353B2 (ja) 2013-04-05 2017-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジニルピラゾロキノリン化合物
US9573947B2 (en) 2013-04-05 2017-02-21 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
SG10202113199RA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
CN114560862A (zh) * 2022-03-08 2022-05-31 山东龙辰药业有限公司 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法
WO2024099416A1 (zh) * 2022-11-10 2024-05-16 上海海和药物研究开发股份有限公司 一种稠合三环类parp1抑制剂、其制备方法及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4035893A (en) 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
WO1993017025A1 (en) 1992-02-19 1993-09-02 The Upjohn Company 3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity
DK31093D0 (pl) 1993-03-19 1993-03-19 Novo Nordisk As
AU694554B2 (en) 1994-09-16 1998-07-23 Novo Nordisk A/S {1,2,4}triazolo{4,3-a}quinoxalinone derivatives, their preparation and use
DK0783504T3 (da) 1994-09-16 2000-08-14 Novo Nordisk As (1,2,4)triazolo (4,3-a)guinoxalinon-derivater, deres fremstilling og anvendelse som antagonister af ampa-receptorer
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
WO2004085439A1 (en) 2003-03-27 2004-10-07 Pfizer Products Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines
CA2612176C (en) 2005-06-14 2015-02-17 Aska Pharmaceutical Co., Ltd. Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors
AU2007282678B2 (en) * 2006-08-08 2012-09-27 Aska Pharmaceutical Co., Ltd. Quinazoline derivative
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
MX2011009314A (es) * 2009-03-05 2011-10-11 Astellas Pharma Inc Compuesto de quinoxalina.

Also Published As

Publication number Publication date
EP2404922A1 (en) 2012-01-11
RU2011140333A (ru) 2013-04-10
EP2404922B1 (en) 2016-11-09
CA2754457A1 (en) 2010-09-10
TW201043632A (en) 2010-12-16
US8674096B2 (en) 2014-03-18
AU2010219598A1 (en) 2011-09-22
JP5609861B2 (ja) 2014-10-22
MX2011009314A (es) 2011-10-11
JPWO2010101230A1 (ja) 2012-09-10
CN102341399A (zh) 2012-02-01
IL214918A0 (en) 2011-11-30
BRPI1009287A2 (pt) 2019-09-24
PT2404922T (pt) 2016-12-22
US20130085134A1 (en) 2013-04-04
US8357688B2 (en) 2013-01-22
EP2404922A4 (en) 2013-07-03
ES2612954T3 (es) 2017-05-19
US20110319385A1 (en) 2011-12-29
WO2010101230A1 (ja) 2010-09-10
KR20110132559A (ko) 2011-12-08

Similar Documents

Publication Publication Date Title
PT2404922T (pt) Compostos de quinoxalina
GB0907425D0 (en) Compounds
EP2393493A4 (en) LINKS
GB0918249D0 (en) Compounds
GB0907515D0 (en) Compounds
GB0914856D0 (en) Compounds
GB0915892D0 (en) Compounds
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
GB0915519D0 (en) Ntithrombotic compounds
GB0909672D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0911000D0 (en) Compounds
EP2443115A4 (en) COMPOUNDS
GB0902796D0 (en) Compounds
GB0918473D0 (en) Compounds
GB0905062D0 (en) Compounds
GB0905060D0 (en) Compounds
GB0905057D0 (en) Compounds
GB0905054D0 (en) Compounds
GB0903948D0 (en) Compounds
GB0903492D0 (en) Compounds
GB0906378D0 (en) Compounds
GB0902391D0 (en) Compounds
GB0902259D0 (en) Compounds